Prm109 - Exploring the Use and Acceptance of Alternative Survival Modelling Approaches for Immuno-Oncology Therapies in Uk Technology Assessments

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2230
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Prm64 - The Need for Innovative Survival Modelling Approaches in Health Technology Assessments (Hta) of Early-Stage Oncology Indications

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Prm148 - Health Technology Assessment Agency Appraisal of Immuno-Oncology Cure Fraction Survival Modelling

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Small Molecules Drive Big Improvements in Immuno-Oncology Therapies

Angewandte Chemie
2018English

Small Molecules Drive Big Improvements in Immuno-Oncology Therapies

Angewandte Chemie - International Edition
CatalysisChemistry
2018English

Immuno-Oncology: The Next Generation of Breakthrough Therapies. Highlights From the Society for Medicines Research Symposium. Oxford, UK - June 21, 2019

Drugs of the Future
Pharmacology
2019English

The Role of Radiation Oncology in Immuno‐Oncology

Oncologist
Cancer ResearchMedicineOncology
2019English

Immuno‐oncology for Surgeons

British Journal of Surgery
Surgery
2019English

Immuno‐Oncology Forum

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2019English

Pcn303 - Assessing the Value of Novel Immuno-Oncology (I-O) Therapies: How Consistent Is the Health Technology Assessment (Hta) Bodies' Consideration of the Survival Benefit in the Absence of Long-Term Data?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy